Third, the heterogeneity of consolidation regimens, particularly among non-GO patients, may have impacted outcomes, despite the fact that survival in the non-GO group was consistent with other contemporary CBF-AML cohorts. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.